Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Bacterial Outer Membrane Vesicles (OMVs)-based Dual Vaccine for Influenza A H1N1 Virus and MERS-CoV.

Mahmoud M Shehata | Ahmed Mostafa | Lisa Teubner | Sara H Mahmoud | Ahmed Kandeil | Rabeh Elshesheny | Renate Frantz | Luigi La Pietra | Stephan Pleschka | Ahmed Osman | Ghazi Kayali | Trinad Chakraborty | Mohamed A Ali | Mobarak Abu Mraheil
Vaccines | 2019

Vaccination is the most functional medical intervention to prophylactically control severe diseases caused by human-to-human or animal-to-human transmissible viral pathogens. Annually, seasonal influenza epidemics attack human populations leading to 290-650 thousand deaths/year worldwide. Recently, a novel Middle East Respiratory Syndrome Coronavirus emerged. Together, those two viruses present a significant public health burden in areas where they circulate. Herein, we generated a bacterial outer membrane vesicles (OMVs)-based vaccine presenting the antigenic stable chimeric fusion protein of the H1-type haemagglutinin (HA) of the pandemic influenza A virus (H1N1) strain from 2009 (H1N1pdm09) and the receptor binding domain (RBD) of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) (OMVs-H1/RBD). Our results showed that the chimeric antigen could induce specific neutralizing antibodies against both strains leading to protection of immunized mice against H1N1pdm09 and efficient neutralization of MERS-CoV. This study demonstrate that OMVs-based vaccines presenting viral antigens provide a safe and reliable approach to protect against two different viral infections.

Pubmed ID: 31141982

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, International
    Id: HHSN272201400006C
  • Agency: Science and Technology Development Fund (STDF) in Egypt, International
    Id: 5175
  • Agency: DFG-funded Collaborative Research Centres 1021, International
    Id: T. C1
  • Agency: Transregional Collaborative Research Centre TRR 84, International
    Id: TP A4
  • Agency: German Centre for Infection Research, International
    Id: TTU 01.803
  • Agency: NRC-internal project, International
    Id: TT110801
  • Agency: Bundesministerium für Bildung und Forschung, International
    Id: PROANTILIS

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Promega (tool)

RRID:SCR_006724

An Antibody supplier

View all literature mentions

Vero C1008 (tool)

RRID:CVCL_0574

Cell line Vero C1008 is a Spontaneously immortalized cell line with a species of origin Chlorocebus sabaeus

View all literature mentions

MDCK (tool)

RRID:CVCL_0422

Cell line MDCK is a Spontaneously immortalized cell line with a species of origin Canis lupus familiaris

View all literature mentions

BALB/cAnNCrl (tool)

RRID:MGI:2683685

laboratory mouse with name BALB/cAnNCrl from MGI.

View all literature mentions

Vero C1008 (tool)

RRID:CVCL_0574

Cell line Vero C1008 is a Spontaneously immortalized cell line with a species of origin Chlorocebus sabaeus

View all literature mentions

BALB/cAnNCrl (tool)

RRID:MGI:2683685

laboratory mouse with name BALB/cAnNCrl from MGI.

View all literature mentions